The decision to structure as a C-corporation (C-corp) is common in the biotech sector, especially for firms seeking venture capital funding. VCs favor C-corporations because the structure protects them and provides various tax benefits, including the Qualified Small Business Stock (QSBS) exclusion under Section 1202 of the federal tax code. 

Biotech firms face unique challenges, especially at the startup stage. Heavily reliant on investment, it’s critical to choose the right corporate and tax structure from the outset, as making changes later on can be costly and complicated, and may impact your ability to attract investment and grant funding. 

The biotech startup ecosystem is unique in many ways, especially given that many operate for several years without generating any revenue, and the bulk of their funding comes from multiple sources, primarily grants, venture capital, and research partnerships. 

Life sciences companies, especially pre-revenue startups, are inordinately impacted by taxation. On the one hand, the R&D credit provides significant tax relief, covering up to 25% of qualified expenses; on the other hand, Section 174 requires some costs to be amortized over a period of years. 

The R&D credit is a critical benefit for life sciences companies and other research-focused organizations. With the ability to cover up to 25% of qualified costs, the credit can significantly ease the tax burden, fuel innovation, and improve cash flow, even for pre-revenue companies. 

Section 174 reform under the One Big Beautiful Bill Act (OBBB) was a major turning point for companies heavily invested in R&E. As of the 2025 tax year, R&E expenses can be claimed immediately rather than being capitalized and amortized over several years. 

Success in life sciences is as much about financial planning and timing as it is about the mission itself. Research and development (R&D), clinical trials, and regulatory approvals are resource-heavy and typically funded through investment, requiring meticulous financial management, reporting, and planning to ensure plans stay on track. 

Financial reporting is an essential accounting practice for all businesses. Factual financial reports inform planning and critical business decisions and are required for stakeholder edification, especially in life sciences, which relies heavily on funding from investors and grant organizations.

Biotech and life sciences firms invest significant resources in research and development. Fortunately, the government recognizes the value of this effort and offers tax credits to offset these costs, which can be a massive support for pre-revenue or unprofitable startups. 

The first 90 days of any startup are the most critical. The decisions you make at this early stage can streamline engagement with investors and regulators, allowing you to focus on your mission without diverting unnecessary time and resources to accounting. 

The life sciences, biotech, MedTech, and pharmaceutical industries are among the most highly regulated industries. Companies in this niche contend with heavy compliance burdens, rapid-fire regulatory changes, and must always be ready for an audit or enforcement, often without advance notice.